Galecto logo
Galecto GLTO
report update icon

Quarterly report 2026-Q2
added 08-10-2026

Galecto Balance Sheet 2025-2011 | GLTO

Brief overview of Galecto's balance sheet structure

This overview follows the five latest available annual observations between 2021 and 2025.

The asset base grew from $122.2 million to $260.5 million, or +113.2%. Average annual growth of roughly 20.8% was strong.

Liabilities grew faster than assets: +303.6% versus +113.2%. A substantial part of expansion was externally funded.

The equity ratio reached 92.3% from 95.9%. A high capital share reduces dependence on liabilities.

The period ended with net cash: net debt stood at -$257.6 million. This supports financial flexibility.

Cash accounts for 98.9% of assets versus 51.2% initially. The change indicates the degree of financial flexibility.

The accumulated result is -$487.4 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.

Overall picture

Galecto's balance sheet sends more positive than negative signals, but liabilities should not begin outpacing the capital base.

Annual Balance Sheet Galecto

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-258 M -14.1 M -21.2 M -32 M -61.7 M -163 M -11 M -31 M - - - - - - -

Long Term Debt

53 K 61 K 66 K 328 K 448 K - - - - - - - - - -

Long Term Debt Current

15 K 12 K 183 K 476 K 399 K 374 K - - - - - - - - -

Total Non Current Liabilities

- - - - - 541 K 211 K - - - - - - - -

Total Current Liabilities

20.1 M 1.2 M 5.83 M 11.1 M 4.54 M 5.57 M - - - - - - - - -

Total Liabilities

20.1 M 1.3 M 5.9 M 11.4 M 4.99 M 6.11 M 8.14 M 4.44 M - - - - - - -

Retained Earnings

-487 M -278 M -256 M -218 M -156 M -104 M -69.5 M -33 M - - - - - - -

Total Assets

261 M 17.1 M 38.2 M 73.2 M 122 M 172 M 56.6 M 35.1 M - - - - - - -

Cash and Cash Equivalents

258 M 14.2 M 21.5 M 32.8 M 62.6 M 164 M 11.5 M - - - - - - - -

Book Value

240 M 15.8 M 32.3 M 61.8 M 117 M 165 M 48.5 M 30.7 M - - - - - - -

Total Shareholders Equity

240 M 15.8 M 32.3 M 61.8 M 117 M 165 M -71.1 M - - - - - - - -

All numbers in USD currency

Quarterly Balance Sheet Galecto

2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- - 61 K 57 K 60 K 60 K 61 K - - - 66 K 112 K 206 K 234 K 328 K 440 K - 402 K 448 K 511 K 635 K 544 K 541 K 541 K 541 K 541 K 211 K 211 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

20.1 M 23.8 M 1.3 M 2.73 M 2.74 M 1.66 M 1.3 M 2.44 M 3.71 M 4.32 M 5.9 M 12.7 M 15.1 M 14.3 M 11.4 M 9.3 M - 7.62 M 4.99 M 6.25 M 5.39 M 6.08 M 6.11 M 6.11 M 6.11 M 6.11 M 8.14 M 8.14 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-487 M -515 M -278 M -287 M -283 M -280 M -278 M -271 M -267 M -262 M -256 M -250 M -241 M -231 M -218 M -204 M - -173 M -156 M -143 M -130 M -118 M -104 M -104 M -104 M -104 M -69.5 M -69.5 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

261 M 535 M 17.1 M 10.7 M 13.7 M 15.4 M 17.1 M 23.4 M 27.3 M 32.5 M 38.2 M 50 M 58.8 M 64.6 M 73.2 M 82 M - 109 M 122 M 136 M 147 M 159 M 172 M 172 M 172 M 172 M 56.6 M 56.6 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

14.2 M 533 M 21.5 M 7.61 M 10.2 M 11.9 M 14.2 M 19.7 M 22.9 M 21.1 M 21.5 M 23.1 M 23 M 25.1 M 32.8 M 28.3 M 29.8 M 45.4 M 62.6 M 66.2 M 68.6 M 74.3 M 164 M 164 M 164 M 164 M 11.3 M 11.3 M - - 31.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Book Value

240 M 512 M 15.8 M 8.01 M 11 M 13.7 M 15.8 M 20.9 M 23.6 M 28.2 M 32.3 M 37.4 M 43.7 M 50.3 M 61.8 M 72.7 M - 101 M 117 M 130 M 141 M 153 M 165 M 165 M 165 M 165 M 48.5 M 48.5 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

15.8 M 512 M 32.3 M 8.01 M 11 M 13.7 M 15.8 M 20.9 M 23.6 M 28.2 M 32.3 M 37.4 M 43.7 M 50.3 M 61.8 M 72.7 M 85.1 M 101 M 117 M 130 M 141 M 153 M 165 M 165 M 165 M 165 M -71.1 M -71.1 M -41.9 M - -33.8 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Galecto, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
FSD Pharma FSD Pharma
HUGE
- 5743.5 % $ 69.7 M canadaCanada
Synthetic Biologics Synthetic Biologics
SYN
- 1.32 % $ 16.2 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Corner Growth Acquisition Corp. Corner Growth Acquisition Corp.
COOL
- -0.89 % $ 114 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Qilian International Holding Group Limited Qilian International Holding Group Limited
QLI
- -6.08 % $ 184 M chinaChina
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
- 1.35 % $ 17.8 M chinaChina
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Abcam plc Abcam plc
ABCM
- - $ 4.9 B britainBritain
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Генетико Генетико
GECO
- - - russiaRussia
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Hepion Pharmaceuticals Hepion Pharmaceuticals
HEPA
- -18.79 % $ 39.3 K usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Codexis Codexis
CDXS
$ 1.46 2.82 % $ 127 M usaUSA
Ardelyx Ardelyx
ARDX
$ 3.78 1.89 % $ 911 M usaUSA
Affimed N.V. Affimed N.V.
AFMD
- -34.95 % $ 21.5 M germanyGermany
ОЗОН Фармацевтика ОЗОН Фармацевтика
OZPH
- - - russiaRussia
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 23.9 1.01 % $ 3.04 B usaUSA
Assembly Biosciences Assembly Biosciences
ASMB
$ 36.6 1.3 % $ 410 M usaUSA
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
- -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Adial Pharmaceuticals Adial Pharmaceuticals
ADIL
$ 7.12 6.91 % $ 4.76 M usaUSA
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Gracell Biotechnologies Gracell Biotechnologies
GRCL
- - $ 3.37 B chinaChina
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 206.68 0.16 % $ 10.3 B usaUSA
GlycoMimetics GlycoMimetics
GLYC
- 9357.83 % $ 1.01 B usaUSA
AnaptysBio AnaptysBio
ANAB
$ 56.8 0.94 % $ 1.63 B usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 66.53 0.15 % $ 12.8 B usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Bicycle Therapeutics plc Bicycle Therapeutics plc
BCYC
$ 4.3 1.42 % $ 298 M britainBritain
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
ChromaDex Corporation ChromaDex Corporation
CDXC
- -0.88 % $ 598 M usaUSA